Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
US Stock Futures Tumble; Jobs Report In Focus
Novartis Announces EU approval for Farydak
Amgen Biosimilar Rival Delayed After Zarxio Launch (Investor's Business Daily)
Related ZIOP
ZIOPHARM Announces Cancer Research Publication of Study Demonstrating Preferential Targeting of Solid Tumor Cells by Modified CAR T Cells
10 Biotech Stocks With Catalysts Coming Soon

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jun 2015Bryan GarnierUpgradesNeutralBuy
Mar 2015NatixisUpgradesNeutralBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

Get Benzinga's Newsletters